Compare NWTG & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | GRDX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.3M |
| IPO Year | N/A | N/A |
| Metric | NWTG | GRDX |
|---|---|---|
| Price | $1.17 | $2.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.1K | ★ 109.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.21 | N/A |
| Revenue Next Year | $40.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $1.87 |
| 52 Week High | $2.23 | $5.30 |
| Indicator | NWTG | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 46.73 |
| Support Level | $1.09 | $1.99 |
| Resistance Level | $1.70 | $2.73 |
| Average True Range (ATR) | 0.14 | 0.24 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 27.58 | 22.78 |
Newton Golf Co Inc is a technology-forward golf company dedicated to revolutionizing the sport with cutting-edge, high-performance products. The company's expanding portfolio includes golf shafts, putters, grips, and other golf-related accessories designed for golfers of all skill levels. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf, as well as through mass merchants and corporate customers in the Americas, Asia, and Europe.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.